A national pharmacare plan should cover what’s best for patients, not what’s new

Using insulin is always challenging, so access to a broad range of appropriate options is vital.

Can biotechnology put patients’ needs ahead of profits?

These are challenging dilemmas for a government that gutted a suite of policies designed to cap excessive drug prices, and that ‘waxed lyrical’ about the importance of accelerating vaccine access worldwide, then failed to support an intellectual property waiver that would expand global production of COVID-19 vaccines.